Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella
This article was originally published in The Pink Sheet Daily
Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.
You may also be interested in...
Europe’s top medical advisory panel turns down a new acute heart failure therapy from Novartis, but gives positive opinions to three other new active substances, from GlaxoSmithKline, Bayer and Takeda, following its Jan. 20-23 meeting.
Pfizer’s Olivier Brandicourt, who has specialized in emerging markets and infectious diseases, inherits Bayer’s health care division, which is in the midst of several product launches and has few near-term patent expirations. Bayer has one of the largest exposures to emerging markets among large pharma companies.
The broadly experienced pharmaceutical executive – who has specialized particularly in emerging markets and infectious diseases – inherits a healthcare division that is in the midst of several product launches and has few near-term patent expirees.